ALZPROTECT
AlzProtect is a biopharmaceutical company developing drug candidates from discovery to clinical trials for the treatment of neurodegenerative diseases including Alzheimer's disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).
ALZPROTECT
Industry:
Biotechnology Clinical Trials Medical Pharmaceutical
Founded:
2007-01-01
Address:
Street, Maryland, United States
Country:
United States
Website Url:
http://www.alzprotect.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
20.2 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API Joomla!
Similar Organizations
Affinivax
Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
OncBioMune
.OncBioMune is a biopharmaceutical company that develops medicines and vaccines to treat novel cancer and stimulate the immune system.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Alzprotect
Xerys
Xerys investment in Series B - Alzprotect
Finovam Gestion
Finovam Gestion investment in Series A - Alzprotect
Nord France Amorcage
Nord France Amorcage investment in Series A - Alzprotect
Finorpa
Finorpa investment in Venture Round - Alzprotect
Eurasante
Eurasante investment in Non Equity Assistance - Alzprotect
Official Site Inspections
http://www.alzprotect.com Semrush global rank: 6.53 M Semrush visits lastest month: 1.05 K
- Host name: cluster011.ovh.net
- IP address: 213.186.33.40
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Alzprotect"
Alzprotect - About the Company
Alzprotect develops drug candidates for the treatment of neurodegenerative diseases. Alzprotect is a biopharmaceutical company that develops drug candidates, from their discovery to clinical …See details»
Alzprotect - Crunchbase Company Profile & Funding
AlzProtect is a biopharmaceutical company developing drug candidates from discovery to clinical trials for the treatment of neurodegenerative diseases including Alzheimer's disease (AD) and …See details»
Alzprotect - Team
Her strategic approach of research and her industrial experience are valuable for the development of Alzprotect. Philippe Verwaerde Président d’Alzprotect . Scientific Advisory Board. Philippe Amouyel MD, PhD. A former medical …See details»
AlzProtect Company Profile - Office Locations, Competitors ... - Craft
AlzProtect has 5 employees across 2 locations and $19.83 m in total funding,. See insights on AlzProtect including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Alzprotect - Overview, News & Similar companies | ZoomInfo.com
Jun 22, 2021 Alzprotect Awarded a Grant from The Michael J. Fox Foundation to Advance Small Molecule Parkinson’s Disease Program Alzprotect, a French biopharmaceutical company has …See details»
Alzprotect - Contacts, Employees, Board Members, Advisors
Alzprotect has 3 current employee profiles, including CEO & General manager Laurent Dupire. Laurent Dupire CEO & General manager Philippe Verwaerde President and CSOSee details»
Alzprotect - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Non Equity Assistance - …See details»
Alzprotect - Partners
Life science cluster organization based in Flanders, Belgium. ... Expertise; AZP2006; News; Investors; Patients; Press; Alzprotect. 85 Rue Nelson Mandela 59120 Loos France Tel. +33 972 649 757. Contact. We use cookies on our …See details»
ALZPROTECT corporate video 2022 - YouTube
Alzprotect imagines and develops therapeutic solutions to slow down or stop neurodegenerative diseases and restore patients’ brain capacity.See details»
Alzprotect Strengthens Its Intellectual Property Portfolio for Its ...
Nov 23, 2020 Founded in 2007, Alzprotect is a French Lille-based company created by Dr. André Delacourte, one of the pioneers of research on Alzheimer's disease, and Dr. Patricia …See details»
☑️Alzprotect — Consulting Organization from France, …
Alzprotect — Consulting Organization from France, has experience with The Seventh Framework Programme, it`s involved in Health, Laboratory & Measurement sectorsSee details»
ALZPROTECT Receives Positive Feedback From EMA and FDA on …
Mar 13, 2024 Alzprotect plans to initiate a randomized Phase 2b/3 proof of concept for PSP and expand its drug development to include Parkinson’s disease, Alzheimer’s disease, and …See details»
Alzprotect Forges Ahead with First Patients Enrolled in Phase 2a …
Sep 14, 2020 With EZEPROGIND, Alzprotect is targeting two neurodegenerative diseases: Progressive Supranuclear Palsy (PSP), for which there is no treatment to date, and …See details»
Alzprotect - Figures & Markets
Nov 6, 2007 Alzprotect raised a total of over 20 million euros, including 14 million € in 2017 to finance the conduct of a first phase 2 study to prove and measure the efficacy of AZP2006 in …See details»
AZP2006, a new promising treatment for Alzheimer’s and related …
Alzprotect Study Goal and Principal Findings: Progranulin (PGRN) is a protein with multiple functions including the regulation of neuroinflammation, neuronal survival, neurite and …See details»
AZP2006, a new promising treatment for Alzheimer's and related …
Aug 19, 2021 3 Alzprotect, Parc Eurasanté, 85C rue Nelson Mandela, 59120, Loos, France. 4 Neuro-Sys, 410 Chemin Départemental 60, 13120, Gardanne, France. PMID: 34413330 …See details»
Alzprotect - Vision
Alzprotect’s objective is to develop new molecules for the treatment of neurodegenerative diseases. Our team uses innovative treatment strategy and modes of action, quite different …See details»
AZP2006, a New Promising Treatment for Progressive …
Dec 25, 2023 Background. Progressive Supranuclear Palsy (PSP) is a rare progressive, fatal neurodegenerative 4-repeat tauopathy. AZP2006 (INN: Ezeprogind) is a first-in-class disease …See details»
Alzprotect - Alzprotect announces the WHO approval of generic …
Lille (France), August 31st – Alzprotect a biopharmaceutical organization developing therapeutic solutions for neurodegenerative diseases announces today that the World Health Organization …See details»